All In Biotech

Free tool

FAERS Monitor: Mepron

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020500 or its brand name (Mepron, Atovaquone). Reports on generic versions are filed under their own applications.

Reports

8,218

Serious

7,018

85% of reports

Hospitalization

4,183

Death reported

1,382

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use833
  • pyrexia453
  • diarrhoea435
  • drug ineffective426
  • nausea406
  • pneumonia393
  • death323
  • fatigue313
  • dyspnoea298
  • acute kidney injury292
  • neutropenia279
  • condition aggravated278
  • rash276
  • vomiting272
  • thrombocytopenia269

Reports by year received

View as table
YearReports
200442
200552
200652
200760
200882
2009105
201090
201189
2012126
2013134
2014170
2015209
2016240
2017272
2018373
2019403
2020570
2021668
2022836
2023956
2024993
2025986
2026710

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,941 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
thrombocytopeniaSignal2696.25.51,163
neutropeniaSignal2795.34.7963
acute kidney injurySignal2924.94.4905
pyrexiaSignal4533.43.1757
pneumoniaSignal3933.12.8568
off label useSignal8332.42.3734
condition aggravatedSignal2782.32.1215
diarrhoea4351.71.6136
rash2761.61.466
vomiting2721.51.343
dyspnoea2981.31.227
nausea4061.31.231
fatigue3131.00.90
death3231.00.91
drug ineffective4260.80.816

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.